These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20460141)

  • 1. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.
    Rizos EN; Chatziioannou S; Siafakas N; Douzenis A; Katsantoni E; Mandrapilia A; Bacalis S; Fotiadis C; Lykouras L
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1135-6. PubMed ID: 20460141
    [No Abstract]   [Full Text] [Related]  

  • 2. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan.
    Rizos EN; Chatziioannou S; Douzenis A; Siafakas N; Katsantoni E; Nikolaidou P; Papathanasiou M; Lykouras L
    Eur Neuropsychopharmacol; 2010 Feb; 20(2):132-6. PubMed ID: 19740630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.
    Yoder KK; Hutchins GD; Morris ED; Brashear A; Wang C; Shekhar A
    Schizophr Res; 2004 Dec; 71(2-3):371-5. PubMed ID: 15474908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone induced tardive cervical dystonia.
    Kutlu A; Dündar S; Altun NS; Budak F
    Psychopharmacol Bull; 2009; 42(4):64-8. PubMed ID: 20581794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL; Su TP; Chou YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
    Zink M; Mase E; Dressing H
    Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in Pisa syndrome and tardive dyskinesia following aripiprazole treatment.
    Shan JC; Tseng MC
    J Neuropsychiatry Clin Neurosci; 2009; 21(3):350-1. PubMed ID: 19776324
    [No Abstract]   [Full Text] [Related]  

  • 8. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
    Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
    Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of tardive dyskinesia with risperidone: a case report.
    Kooptiwoot S; Settachan T
    J Med Assoc Thai; 2000 Nov; 83(11):1430-2. PubMed ID: 11215878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.
    Trugman JM; Leadbetter R; Zalis ME; Burgdorf RO; Wooten GF
    Mov Disord; 1994 Jul; 9(4):441-6. PubMed ID: 7969212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone (Geodon) for schizophrenia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
    [No Abstract]   [Full Text] [Related]  

  • 13. Tardive dyskinesia and ziprasidone.
    Rosenquist KJ; Walker SS; Ghaemi SN
    Am J Psychiatry; 2002 Aug; 159(8):1436. PubMed ID: 12153846
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.
    Wessels AM; Bies RR; Pollock BG; Schneider LS; Lieberman JA; Stroup S; Li CH; Coley K; Kirshner MM; Marder SR
    J Clin Pharmacol; 2011 Nov; 51(11):1587-91. PubMed ID: 21209243
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine.
    Bjorklund NL; Sorg BA; Schenk JO
    Synapse; 2008 Oct; 62(10):736-45. PubMed ID: 18651643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziprasidone: a novel psychotropic with unique properties.
    Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
    Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.